ITTO20040621A1 - Immunogeno sintetico per la terapia e profilassi dell'abuso di droghe e sostanze psicoattive - Google Patents
Immunogeno sintetico per la terapia e profilassi dell'abuso di droghe e sostanze psicoattiveInfo
- Publication number
- ITTO20040621A1 ITTO20040621A1 IT000621A ITTO20040621A ITTO20040621A1 IT TO20040621 A1 ITTO20040621 A1 IT TO20040621A1 IT 000621 A IT000621 A IT 000621A IT TO20040621 A ITTO20040621 A IT TO20040621A IT TO20040621 A1 ITTO20040621 A1 IT TO20040621A1
- Authority
- IT
- Italy
- Prior art keywords
- misusing
- psychoactive
- prophylaxis
- drugs
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2003127705/15A RU2236257C1 (ru) | 2003-09-15 | 2003-09-15 | Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами |
Publications (1)
Publication Number | Publication Date |
---|---|
ITTO20040621A1 true ITTO20040621A1 (it) | 2004-12-15 |
Family
ID=33434130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT000621A ITTO20040621A1 (it) | 2003-09-15 | 2004-09-15 | Immunogeno sintetico per la terapia e profilassi dell'abuso di droghe e sostanze psicoattive |
Country Status (5)
Country | Link |
---|---|
DE (1) | DE102004044666A1 (fr) |
EA (1) | EA006248B1 (fr) |
FR (1) | FR2859633A1 (fr) |
IT (1) | ITTO20040621A1 (fr) |
RU (1) | RU2236257C1 (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ568211A (en) | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
US20110180430A1 (en) | 2005-11-04 | 2011-07-28 | Novartis Vaccines And Diagnostics Srl | Adjuvanted influenza vaccines including cytokine-inducing agents |
CA2628152C (fr) | 2005-11-04 | 2016-02-02 | Novartis Vaccines And Diagnostics S.R.L. | Vaccins avec adjuvant comprenant des antigenes sans virions prepares a partir de virus influenza eleves en culture cellulaire |
DK1976559T6 (da) | 2006-01-27 | 2020-04-06 | Seqirus Uk Ltd | Influenzavacciner indeholdende hæmagglutinin og matrixproteiner |
EP2004226A1 (fr) | 2006-03-24 | 2008-12-24 | Novartis Vaccines and Diagnostics GmbH & Co. KG | Stockage de vaccins antigrippaux sans refrigeration |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
CA2663196A1 (fr) | 2006-09-11 | 2008-03-20 | Novartis Ag | Fabrication de vaccins contre le virus grippal sans utiliser d'oeufs |
NZ577405A (en) | 2006-12-06 | 2012-08-31 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
EA201070066A1 (ru) | 2007-06-27 | 2010-06-30 | Новартис Аг | Вакцины против гриппа с низким содержанием добавок |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
EP2268309B1 (fr) | 2008-03-18 | 2015-01-21 | Novartis AG | Améliorations dans la préparation des antigènes pour le vaccin contre le virus de la grippe |
US8568732B2 (en) | 2009-03-06 | 2013-10-29 | Novartis Ag | Chlamydia antigens |
PL2510947T3 (pl) | 2009-04-14 | 2016-09-30 | Kompozycje do immunizacji przeciwko Staphylococcus aureus | |
DE102010018462A1 (de) | 2009-04-27 | 2011-04-07 | Novartis Ag | Impfstoffe zum Schutz gegen Influenza |
SG177533A1 (en) | 2009-07-07 | 2012-02-28 | Novartis Ag | Conserved escherichia coli immunogens |
DK3178490T3 (da) | 2009-07-15 | 2022-06-20 | Glaxosmithkline Biologicals Sa | RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse |
CN102770443A (zh) | 2009-07-16 | 2012-11-07 | 诺华有限公司 | 脱毒大肠杆菌免疫原 |
GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
WO2011080595A2 (fr) | 2009-12-30 | 2011-07-07 | Novartis Ag | Immunogènes de polysaccharide conjugués à des protéines porteuses de e. coli |
GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
EP3527224A1 (fr) | 2011-01-26 | 2019-08-21 | GlaxoSmithKline Biologicals S.A. | Régime d'immunisation contre le vrs |
PT2707385T (pt) | 2011-05-13 | 2017-12-19 | Glaxosmithkline Biologicals Sa | Antigénios de f de rsv pré-fusão |
AU2012335208B2 (en) | 2011-11-07 | 2017-08-31 | Glaxosmithkline Biologicals S.A. | Carrier molecule comprising a spr0096 and a spr2021 antigen |
EA201590427A1 (ru) | 2012-10-02 | 2015-09-30 | Глаксосмитклайн Байолоджикалс С.А. | Нелинейные сахаридные конъюгаты |
RU2526807C2 (ru) * | 2012-11-28 | 2014-08-27 | Общество с ограниченной ответственностью "ДИАМЕДИКА" ООО "ДИАМЕДИКА" | Синтетический иммуноген для защиты от токсического действия наркотических и психоактивных веществ |
CN113424060A (zh) * | 2019-01-31 | 2021-09-21 | 美国西门子医学诊断股份有限公司 | 抗纳洛酮和抗纳曲酮单克隆抗体及其生产和使用方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0967993A4 (fr) * | 1995-12-14 | 2001-04-18 | Scripps Research Inst | Vaccin anti-cocaine |
RU2112543C1 (ru) * | 1996-09-26 | 1998-06-10 | Александр Григорьевич Хоменко | Иммуномодулирующее лекарственное средство |
RU2148412C1 (ru) * | 1999-08-06 | 2000-05-10 | Москаленко Екатерина Петровна | Способ получения протективного коклюшного антигена |
-
2003
- 2003-09-15 RU RU2003127705/15A patent/RU2236257C1/ru not_active IP Right Cessation
-
2004
- 2004-09-14 EA EA200401080A patent/EA006248B1/ru not_active IP Right Cessation
- 2004-09-15 IT IT000621A patent/ITTO20040621A1/it unknown
- 2004-09-15 DE DE102004044666A patent/DE102004044666A1/de not_active Withdrawn
- 2004-09-15 FR FR0409762A patent/FR2859633A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
EA006248B1 (ru) | 2005-10-27 |
FR2859633A1 (fr) | 2005-03-18 |
RU2236257C1 (ru) | 2004-09-20 |
EA200401080A1 (ru) | 2005-04-28 |
DE102004044666A1 (de) | 2005-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ITTO20040621A1 (it) | Immunogeno sintetico per la terapia e profilassi dell'abuso di droghe e sostanze psicoattive | |
CY2018005I1 (el) | Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης | |
CY2015003I1 (el) | Φαρμακευτικες συνθεσεις για θεραπεια καρκινου | |
ATE296619T1 (de) | Feste orale dosierungsform von simethicon | |
DE50206657D1 (de) | Pharmazeutische zusammensetzung zur behandlung von multiple sklerose | |
DE60220661D1 (de) | Transdermales pflaster zur verabreichung von fentanyl | |
IS7714A (is) | Lyfjasamsetningar úr módafíníl | |
FIU20060389U0 (fi) | Luusairauksien hoito | |
IL164784A0 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
IS7691A (is) | Lyfjasamsetningar til að meðhöndla æxli | |
DE60322451D1 (de) | 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung | |
BRPI0209720A2 (pt) | dosagem e embalagem de medicação com liberação controlada | |
IS2707B (is) | Nýjar lyfjasamsetningar úr módafíníli | |
NO20042208L (no) | Vaginalt administrerte anti-dysrytmiske midler for behandling av bekkensmerter | |
ITMI20020773A1 (it) | Farmaci per il trattamento dell'artrite | |
FI20000780A (fi) | Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi | |
ATE405293T1 (de) | Selbstemulgierende und selbstmicroemulgierende formulierungen zur oralen verabreichung von taxoiden | |
HK1077572A1 (en) | Pharmaceutical salts of reboxetine | |
EE200300468A (et) | Pravastatiini stabiilne farmatseutiline kompositsioon | |
NO20043633L (no) | Oral doseringsform for kontrollert medikamentfrigivning | |
EP1361866A4 (fr) | Emulsions en formes posologiques solides pour l'administration orale | |
ITMI20011284A0 (it) | Composizione farmaceutica per il trattamento dell'iperfosfatemia | |
TR200400375T3 (tr) | Taksanlarin sabit araliklarla dozlanmasi | |
ITMI20020693A1 (it) | Sostanze composizioni e metodi per il trattamento dell'alopecia androgenetica e dell'ipersecrezione sebacea | |
ITMO20030065A1 (it) | Dispositivo per l'ancoraggio di lastre ceramiche. |